Leap Therapeutics Q3 2020 Earnings Report
Key Takeaways
Leap Therapeutics reported a net loss of $7.1 million for the third quarter of 2020, compared to a net loss of $7.9 million for the same period in 2019. The decrease in net loss was primarily due to revenue recognized from the BeiGene agreement, a decrease in clinical development expenses, and non-cash foreign currency gains.
DKN-01 continues to show potential as a single-agent or combination treatment for biomarker-defined cancer patients.
The first patient was dosed in the combination study of DKN-01 plus tislelizumab for gastric or gastroesophageal junction cancer patients.
Net loss decreased to $7.1 million for the third quarter 2020, compared to $7.9 million for the same period in 2019.
Cash, cash equivalents and marketable securities totaled $58.0 million at September 30, 2020.